RCE Investor Webinar Presentation Deck
Filed with ASX · · 39 pages · English
Summary by 6ix AI
Recce Pharmaceuticals Ltd. has released a presentation deck for an investor webinar, detailing its clinical programs and company overview. The presentation highlights the company's development of a new class of synthetic anti-infectives aimed at addressing antibiotic resistance. The document emphasizes the strategic partnership with PT Etana Biotechnologies to accelerate clinical programs in Southeast Asia.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Recce Pharmaceuticals Ltd. on 6ix
In the deck
Earlier from Recce Pharmaceuticals
- Appendix 4D and Interim Financial Report
- Recce Enters Second U.S. Department of Defense R&D Agreement
- Quarterly Activities/Appendix 4C Cash Flow Report
- AUD $5.3m R&D Rebate Received
- RCE Awarded Advanced Overseas Finding up to A$85m
Later from Recce Pharmaceuticals
- Brazil Patent Granted for RECCE Anti-Infectives
- Recce Signs Middle East Licensing Term Sheet
- Addendum to Recce Signs Middle East Licensing Term Sheet
- HREC Approval Accelerates Global Phase 3 DFI Strategy
- Placement & SPP to raise $8 million
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals